Neil B. Minkoff, MD

home / authors / neil-b-minkoff-md

Articles

November 15th 2021

Optimizing Outcomes for Patients With CKD and T2DM

Neil B. Minkoff, MD Rajiv Agarwal, MD, MS Eugene Wright Jr., MD George L. Bakris, MD

Steps that need to be taken to address unmet needs and optimize outcomes for patients who have chronic kidney disease and type 2 diabetes.

November 15th 2021

Emerging Therapies for Chronic Kidney Disease

Neil B. Minkoff, MD George L. Bakris, MD Eugene Wright Jr., MD

An overview of therapies in the pipeline, including other nonsteroidal MRAs, that show potential in treating patients who have chronic kidney disease and type 2 diabetes.

November 15th 2021

SGLT2 Inhibitor Use in Chronic Kidney Disease

Neil B. Minkoff, MD Eugene Wright Jr., MD George L. Bakris, MD

A panel of clinicians react to limitations surrounding the use of SGLT2 inhibitors for patients with chronic kidney disease and type 2 diabetes.

November 11th 2021

Implications of FIDELIO-DKD in CKD

Neil B. Minkoff, MD Eugene Wright Jr., MD

Where data demonstrated by the FIDELIO-DKD study of finerenone for patients with chronic kidney disease may apply in routine clinical practice.

November 11th 2021

Non-steroidal MRAs for Chronic Kidney Disease

Neil B. Minkoff, MD George L. Bakris, MD Rajiv Agarwal, MD, MS

What to know in terms of the mechanism of action of non-steroidal MRA finerenone compared with other therapies used to treat patients with chronic kidney disease and type 2 diabetes.

November 4th 2021

The FIDELIO-DKD Trial in Chronic Kidney Disease

Neil B. Minkoff, MD George L. Bakris, MD

George L. Bakris, MD, describes the design and results of the FIDELIO-DKD trial investigating the effect of finerenone on patients with chronic kidney disease.

November 4th 2021

Chronic Kidney Disease: Treatment Landscape

Neil B. Minkoff, MD George L. Bakris, MD Eugene Wright Jr., MD Rajiv Agarwal, MD, MS

Therapies used to help treat patients who have chronic kidney disease and type 2 diabetes.

October 28th 2021

Establishing Care Pathways to Manage CKD and T2DM

Neil B. Minkoff, MD Rajiv Agarwal, MD, MS George L. Bakris, MD Eugene Wright Jr., MD

Considerations for establishing balance for the care of patients with chronic kidney disease among all types of care settings.

October 28th 2021

Early Identification and Management of CKD

Neil B. Minkoff, MD Eugene Wright Jr., MD Rajiv Agarwal, MD, MS George L. Bakris, MD

What better testing strategies and newer quality measures can do to improve patient referrals to nephrologists for earlier intervention of chronic kidney disease.

October 21st 2021

Measures to Improve Chronic Kidney Disease

Neil B. Minkoff, MD George L. Bakris, MD Eugene Wright Jr., MD

Key takeaways from the National Kidney Foundation’s new HEDIS and MIPS quality measures for patients with chronic kidney disease and type 2 diabetes.

October 21st 2021

Care Coordination for Patients With CKD and T2DM

Neil B. Minkoff, MD George L. Bakris, MD Eugene Wright Jr., MD

Various types of health care professionals who may play a role in treating patients with chronic kidney disease, and recommendations to help overcome barriers that impact risk of disease progression and outcomes for patients.

October 20th 2021

The Promising Future of Alzheimer Disease Treatment

Neil B. Minkoff, MD Mona Chitre, PharmD Michael Cantor, MD Richard Isaacson, MD Dan Gasby

Panelists conclude the discussion with personal insight into the promising future of Alzheimer disease treatment.

October 18th 2021

Disease-Modifying Therapy: Defining Response

Neil B. Minkoff, MD Mona Chitre, PharmD Michael Cantor, MD Richard Isaacson, MD Dan Gasby

Expert panelists consider how to define response to disease-modifying therapies and discuss the threshold for treatment ineligibility due to lack of response.

October 14th 2021

Motivating Patients Who Have CKD and T2DM

Neil B. Minkoff, MD George L. Bakris, MD Eugene Wright Jr., MD Rajiv Agarwal, MD, MS

Strategies that can help clinicians establish and work toward goals when treating patients with chronic kidney disease to help control disease and prevent progression.

October 14th 2021

Preventing Progression of Chronic Kidney Disease

Neil B. Minkoff, MD Rajiv Agarwal, MD, MS George L. Bakris, MD Eugene Wright Jr., MD

A panel of clinicians explain why action is needed to help prevent the risk of progression of chronic kidney disease.

October 13th 2021

The American Brain Foundation: Driving AD Treatment Development

Neil B. Minkoff, MD Mona Chitre, PharmD Michael Cantor, MD Richard Isaacson, MD Dan Gasby

A member of the American Brain Foundation discusses the organization’s role in the development of Alzheimer disease management and improvement in education.

October 11th 2021

Offsetting the Increased Cost of AD Treatment

Neil B. Minkoff, MD Mona Chitre, PharmD Michael Cantor, MD Richard Isaacson, MD Dan Gasby

Key opinion leaders discuss possible ways to mitigate the increased cost of Alzheimer disease treatment.

October 7th 2021

Clinical and Economic Burden of Chronic Kidney Disease

Neil B. Minkoff, MD Eugene Wright Jr., MD Rajiv Agarwal, MD, MS George L. Bakris, MD

Financial and clinical concerns surrounding the burden of chronic kidney disease progression, as well as social determinants that factor into managing the condition in the community.

October 7th 2021

Counseling Patients About Chronic Kidney Disease

Neil B. Minkoff, MD Rajiv Agarwal, MD, MS Eugene Wright Jr., MD George L. Bakris, MD

Strategies to help clinicians talk with patients about chronic kidney disease staging and what to expect in terms of prognosis.

October 6th 2021

Stratifying Patients for Treatment Eligibility

Neil B. Minkoff, MD Mona Chitre, PharmD Michael Cantor, MD Richard Isaacson, MD Dan Gasby

A discussion on the stratification of patient populations for treatment eligibility based on various decision factors.

October 4th 2021

Developing Policies for Early Biomarker Detection

Neil B. Minkoff, MD Mona Chitre, PharmD Michael Cantor, MD Richard Isaacson, MD Dan Gasby

Panelists discuss how to craft future policies for early biomarker detection to use developing therapies that target underlying pathophysiology.

September 30th 2021

Assessment and Staging of Chronic Kidney Disease

Neil B. Minkoff, MD George L. Bakris, MD Eugene Wright Jr., MD

Diagnostic criteria and special considerations of nephrologists when assessing patient kidney function and diagnosing chronic kidney disease.

September 30th 2021

Characteristics of Chronic Kidney Disease

Neil B. Minkoff, MD Rajiv Agarwal, MD, MS Eugene Wright Jr., MD

Drs Rajiv Agarwal and Eugene Wright Jr. highlight risk factors associated with chronic kidney disease and react to concerns surrounding the assessment and treatment of patients.

September 29th 2021

Improving Access to Appropriate AD Care

Neil B. Minkoff, MD Mona Chitre, PharmD Michael Cantor, MD Richard Isaacson, MD Dan Gasby

Key opinion leaders consider effective ways to improve access to appropriate care for individuals with Alzheimer disease.

September 27th 2021

Improved Tracking of AD Comorbidities and Progression

Neil B. Minkoff, MD Mona Chitre, PharmD Michael Cantor, MD Richard Isaacson, MD Dan Gasby

Expert panelists discuss methods to better monitor comorbidities and adverse effects associated with Alzheimer disease.

September 22nd 2021

Goals of AD Therapy With Early Detection

Neil B. Minkoff, MD Mona Chitre, PharmD Michael Cantor, MD Richard Isaacson, MD Dan Gasby

Experts in the management of Alzheimer disease consider the future goals of therapy in tandem with the development of early detection polices.

September 20th 2021

Diagnostic Process for Individuals With Suspected AD

Neil B. Minkoff, MD Mona Chitre, PharmD Michael Cantor, MD Richard Isaacson, MD Dan Gasby

A discussion on the typical journey of a patient with Alzheimer disease from initial presentation to proper diagnosis within the health care system.

September 15th 2021

Key Drivers for Health Care Utilization and Spending

Neil B. Minkoff, MD Mona Chitre, PharmD Michael Cantor, MD Richard Isaacson, MD Dan Gasby

Key opinion leaders discuss which factors contribute to patients and caregivers deciding to seek health care guidance and assistance for Alzheimer disease.

September 13th 2021

Health Inequities Among Patient Populations With AD

Neil B. Minkoff, MD Mona Chitre, PharmD Michael Cantor, MD Richard Isaacson, MD Dan Gasby

A discussion on the disparity in access to quality health care between various patient populations.

September 8th 2021

Increased Prevalence of Alzheimer Disease

Neil B. Minkoff, MD Mona Chitre, PharmD Michael Cantor, MD Richard Isaacson, MD Dan Gasby

Experts in the management of Alzheimer disease consider the increased prevalence of Alzheimer disease in the United States with growing geriatric populations and how the health care system is adapting.

1 2 >